Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trialHideka Inoue, Hiroshi Maegawa, Keiko Fuse et al.|Journal of Diabetes Investigation|2018Cited by 62
Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trialKayo Horibe, Hiroshi Maegawa, Katsutaro Morino et al.|Diabetes Research and Clinical Practice|2022Cited by 27